Global Edition
Global Edition
UK Edition
EU Edition
US Edition

Understand the story, not the spin.

Markets

Tirzepatide cut teens’ BMI 18.5% in 72-week trial

Published 17 November 2026 · All stories from this day

A 72-week randomized trial found that tirzepatide reduced adolescents’ body mass index by an average of 18.5%, while BMI in the placebo group rose 0.5%. More than half of those who received the drug fell below the age- and sex-specific BMI threshold for obesity, and researchers also reported improvements in several metabolic measures and physical comfort.

The phase 3 SURMOUNT-ADOLESCENTS trial included 160 participants aged 12 to 17 with obesity, or overweight and at least one obesity-related complication. They were assigned to weekly tirzepatide or placebo, alongside lifestyle support that included counseling on healthy eating and physical activity. The study ran for 72 weeks at 31 research centers in six countries.

The trial’s 18.5% average BMI reduction counted participants who stopped treatment. In an analysis estimating outcomes if participants continued treatment, the reduction was 21.4%. By comparison, placebo recipients’ BMI increased 0.5%. At week 72, 53.5% of participants receiving tirzepatide had a BMI below the 95th percentile for their age and sex, compared with 7.1% in the placebo group.

A BMI reduction of at least 5% occurred in 79.6% of tirzepatide recipients and...

Now playing
0:00 / 0:00